NASDAQ:DRIO - Nasdaq - US23725P2092 - Common Stock - Currency: USD
DARIOHEALTH CORP
NASDAQ:DRIO (2/10/2025, 8:00:01 PM)
Premarket: 0.64 0 (-0.02%)0.6401
-0.05 (-7.04%)
The current stock price of DRIO is 0.6401 USD. In the past month the price decreased by -30.42%. In the past year, price decreased by -72.76%.
Join us as we delve into today's session and uncover the stocks that are standing out with unusual volume.
Symbol | Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
VEEV | VEEVA SYSTEMS INC-CLASS A | 38.05 | 38.61B | ||
DOCS | DOXIMITY INC-CLASS A | 64.95 | 15.52B | ||
WAY | WAYSTAR HOLDING CORP | N/A | 7.13B | ||
TDOC | TELADOC HEALTH INC | N/A | 2.39B | ||
CERT | CERTARA INC | 35.9 | 2.25B | ||
GDRX | GOODRX HOLDINGS INC-CLASS A | 15.5 | 1.89B | ||
SDGR | SCHRODINGER INC | N/A | 1.83B | ||
PHR | PHREESIA INC | N/A | 1.68B | ||
EVH | EVOLENT HEALTH INC - A | 10.92 | 1.16B | ||
HSTM | HEALTHSTREAM INC | 51.54 | 1.02B | ||
LFMDP | LIFEMD INC - LFMD 8 7/8 PERP | N/A | 971.03M | ||
DH | DEFINITIVE HEALTHCARE CORP | 15.74 | 829.14M |
DarioHealth Corp. is a digital health company which offers a user-centric multi-chronic condition digital therapeutics platform that delivers personalized and dynamic interventions driven by data analytics and one-on-one coaching for diabetes, hypertension, weight management, musculoskeletal pain, and behavioral health. The company is headquartered in New York City, New York and currently employs 249 full-time employees. The company went IPO on 2013-03-08. The firm operates at the intersection of life sciences, behavioral science, and software technology to deliver seamlessly integrated and highly engaging digital therapeutic interventions. Its platform and suite of solutions delivers personalized and dynamic interventions driven by data analytics and one-on-one coaching for diabetes, hypertension, weight management, musculoskeletal pain, and behavioral health. Its products include Dario Blood Pressure Monitoring System and Dario Blood Glucose Monitoring Starter Kit. Dario Blood Glucose Monitoring Starter Kit is a pocket-sized smartphone glucometer that manages diabetes in one ultra-compact device. Dario Blood Pressure Monitoring System is a blood pressure monitoring system used to measure blood pressure, which allows to store all its user readings in the Dario App. Its Dario mobile app is a complete, cloud-based solution for personal chronic condition management.
DARIOHEALTH CORP
322 W 57Th St. #33B
New York City NEW YORK 10019 US
CEO: Erez Raphael
Employees: 223
Company Website: https://shop.mydario.com/
Investor Relations: https://dariohealth.investorroom.com
Phone: 16466654667
The current stock price of DRIO is 0.6401 USD.
The exchange symbol of DARIOHEALTH CORP is DRIO and it is listed on the Nasdaq exchange.
DRIO stock is listed on the Nasdaq exchange.
Always make your own analysis. On these pages you can find a full technical and fundamental analysis report for DRIO, which may be a starting point for your analysis. You can also find the financials, news, analyst ratings and estimates here, which can be used to increase your understanding of DRIO.
DRIO does not pay a dividend.
DRIO does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.03).
The outstanding short interest for DRIO is 11.67% of its float.
ChartMill assigns a fundamental rating of 2 / 10 to DRIO. Both the profitability and financial health of DRIO have multiple concerns.
Over the last trailing twelve months DRIO reported a non-GAAP Earnings per Share(EPS) of -1.03. The EPS decreased by 49.26% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -40.22% | ||
ROE | -75.59% | ||
Debt/Equity | 0.35 |
ChartMill assigns a Buy % Consensus number of 82% to DRIO. The Buy consensus is the average rating of analysts ratings from 9 analysts.
For the next year, analysts expect an EPS growth of 49.5% and a revenue growth 32.07% for DRIO